Tvardi Therapeutics (TVRD) Stock Chart & Stock Price History $23.12 -1.02 (-4.23%) As of 08/7/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock Tvardi Therapeutics Stock Price Performance The Tvardi Therapeutics (TVRD) stock chart highlights key performance trends across multiple timeframes. In the past month, the stock has increased 5.81%, reflecting recent market activity. As of the latest close, Tvardi Therapeutics traded at $23.12 with a market cap of $216.43 million and volume of 13,990 shares. Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-11.76%1 Month Performance+5.81% TVRD Stock Chart for Friday, August, 8, 2025 TVRD Chart by TradingView Tvardi Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/07/2025$24.14$23.12-4.23%$24.34$22.8413,990 shs$216.43 million08/06/2025$25.99$24.14-7.12%$25.49$23.7822,564 shs$225.95 million08/05/2025$26.34$25.99-1.33%$26.69$24.8844,015 shs$243.27 million08/04/2025$26.20$26.34+0.53%$27.76$25.4636,147 shs$246.57 million08/01/2025$25.96$26.20+0.92%$26.45$25.2722,180 shs$245.26 million07/31/2025$25.69$25.96+1.05%$26.55$25.6131,876 shs$242.99 million07/30/2025$25.98$25.69-1.12%$27.05$25.1119,303 shs$240.46 million07/29/2025$24.87$25.98+4.46%$26.62$24.3047,779 shs$243.20 million07/28/2025$26.52$24.87-6.22%$26.31$24.8015,664 shs$232.78 million07/25/2025$27.29$26.52-2.82%$27.72$26.0214,520 shs$248.23 million Get the Latest News and Ratings for TVRD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/24/2025$28.64$27.29-4.71%$28.54$25.9122,924 shs$255.43 million07/23/2025$25.37$28.64+12.89%$28.75$25.5050,788 shs$268.07 million07/22/2025$25.88$25.37-1.97%$26.07$24.4251,369 shs$237.46 million07/21/2025$24.61$25.88+5.16%$25.97$24.4835,463 shs$242.24 million07/18/2025$23.98$24.61+2.63%$25.55$24.0128,374 shs$230.35 million07/17/2025$22.74$23.98+5.45%$25.19$22.3040,187 shs$224.45 million07/16/2025$26.11$22.74-12.91%$25.06$22.7457,131 shs$212.87 million07/15/2025$29.83$26.11-12.47%$30.00$26.0147,545 shs$244.39 million07/14/2025$27.34$29.83+9.11%$31.98$26.6472,682 shs$279.21 million07/11/2025$22.67$27.34+20.60%$27.79$23.0096,236 shs$255.90 million07/10/2025$22.13$22.67+2.44%$22.85$21.8619,929 shs$212.21 million07/09/2025$21.85$22.13+1.28%$22.17$21.3417,989 shs$207.14 million07/08/2025$21.52$21.85+1.53%$22.00$21.1725,737 shs$204.52 million07/07/2025$22.46$21.52-4.19%$22.21$21.1416,890 shs$201.43 million Related Companies Akebia Therapeutics Stock Price Chart Arcus Biosciences Stock Price Chart Anavex Life Sciences Stock Price Chart Collegium Pharmaceutical Stock Price Chart Enliven Therapeutics Stock Price Chart Mineralys Therapeutics Stock Price Chart Sana Biotechnology Stock Price Chart Immunome Stock Price Chart Urogen Pharma Stock Price Chart Zymeworks Stock Price Chart Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TVRD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVRD Stock Alerts